By Lew Kizer — 2026-11-16 — Health & Nutrition
The short answer
In Novo Nordisk's REDEFINE 9 trial of 309 adults without diabetes, two lower doses of the investigational shot CagriSema (1.7/1.7 mg and 1.0/1.0 mg) led to 20.7% and 21.0% average weight loss at 68 weeks, compared with 2.0% on placebo, if people stayed on treatment. Counting everyone regardless of stopping, the figures were 19.4% and 18.6% vs. 4.6%. The results were published Nov. 14, 2026. Novo says an FDA decision on the higher 2.4/2.4 mg dose is expected in the fourth quarter of 2026. CagriSema is not approved.
Key facts
- Novo Nordisk released full REDEFINE 9 results on Nov. 14, 2026, presented at ObesityWeek 2026 and published online in The Lancet Diabetes & Endocrinology (lead author Dr. Sean Wharton, University of Toronto).
- Design: 68-week, randomized, double-blind, placebo-controlled trial of 309 adults with obesity, or overweight plus at least one weight-related condition, without diabetes. Everyone also got lifestyle support.
- If everyone stayed on treatment (efficacy estimand): 20.7% (1.7/1.7 mg) and 21.0% (1.0/1.0 mg) average weight loss vs. 2.0% on placebo.
- Counting everyone regardless of stopping (treatment-regimen estimand): 19.4% and 18.6% vs. 4.6%.
- About half lost at least 20% of body weight (51.3% and 48.3%, efficacy estimand) vs. 2.7% on placebo.
- Waist size fell 17.2 cm and 17.5 cm vs. 3.6 cm on placebo.
- Side effects were mostly gastrointestinal and mild to moderate. Stopping for side effects: 2.9% and 4.9% vs. 4.9% on placebo.
- The trial was not designed to compare the two CagriSema doses with each other.
- Novo filed with the FDA in December 2025 for CagriSema 2.4/2.4 mg and says a decision is expected in Q4 2026.
KINGSPORT, Tenn., Nov. 16, 2026 — Novo Nordisk on Saturday released the full results of its REDEFINE 9 trial, presented at ObesityWeek 2026 in Washington, D.C., and published the same day in The Lancet Diabetes & Endocrinology. Two lower doses of CagriSema, Novo's experimental weekly shot that pairs semaglutide with the amylin medicine cagrilintide, each led to about 21% average weight loss at 68 weeks. Novo also restated that an FDA decision on the full dose is expected before the end of the year.
This article reports medical news and is not medical advice. SmashMeals is a food company, not a medical provider, and is not affiliated with the companies or researchers named here. Talk with your prescriber before you start, stop or change any medicine.
What the trial found
REDEFINE 9 enrolled 309 adults without diabetes who had obesity, or overweight plus at least one weight-related condition. They were randomly assigned to CagriSema 1.7/1.7 mg, CagriSema 1.0/1.0 mg or placebo for 68 weeks, and everyone got lifestyle support.
| At 68 weeks | 1.7/1.7 mg | 1.0/1.0 mg | Placebo |
|---|---|---|---|
| Weight loss, if stayed on treatment | 20.7% | 21.0% | 2.0% |
| Weight loss, everyone counted | 19.4% | 18.6% | 4.6% |
| Lost 10% or more | 87.3% | 86.0% | 13.6% |
| Lost 20% or more | 51.3% | 48.3% | 2.7% |
| Waist reduction | 17.2 cm | 17.5 cm | 3.6 cm |
| Stopped for side effects | 2.9% | 4.9% | 4.9% |
Threshold figures use the "stayed on treatment" (efficacy) estimand. Source: Novo Nordisk's Nov. 14 release.
Reading the 21% headline
Most headlines use the roughly 21% figure. That number estimates results if everyone kept taking the medicine. When the researchers counted every participant, including those who stopped, the average was 19.4% and 18.6%. Both numbers come from the same trial; they answer different questions.
The two lower doses landed close together, but the trial was not built to compare them head to head. It is also not brand-new news: Novo first mentioned the 21% topline in its Nov. 4 quarterly report. What is new is the peer-reviewed paper and the full details. Side effects were mostly gastrointestinal and mild to moderate, and the share who stopped because of side effects was no higher than on placebo.
Novo says it filed with the FDA in December 2025 for the higher 2.4/2.4 mg dose and expects a decision in the fourth quarter of 2026. CagriSema is not approved in the U.S. or anywhere else. Our REDEFINE 1 story covers the full-dose trial.
Where food fits
Whatever the dose, the eating side of these medicines looks familiar: a smaller appetite and less room for anything that does not pull its weight. Our Wegovy meal plan page covers eating on semaglutide, GLP-1 meal planning covers protein and portions with a smaller appetite, and the illustrative 7-day GLP-1 meal plan shows a sample week. None of it replaces advice from your prescriber or a registered dietitian.
“You don't have to figure out the macros. You don't have to wonder if the portions are right. We've already done that work. All you have to do is eat.” — Lew Kizer, Founder, SmashMeals
Planning Thanksgiving around a smaller appetite? Our gluten-free Thanksgiving menu sells smoked turkey, ham, sides and pies one item at a time. Deadlines: Thanksgiving ordering is closed.. Pick up locally or order for shipping; checkout confirms timing. See this week's meals.
Commentary, not medical advice
The SmashMeals perspective
Lower doses that work about as well could matter for people who struggle with side effects, but the eating side looks the same at any dose: a smaller appetite, and protein that has to fit into less food. We cook portioned, protein-forward meals with posted nutrition so that part is already done.
Frequently asked questions
Is the 21% figure new?
Not exactly. Novo mentioned the 21% topline for the 1.0/1.0 mg dose in its Nov. 4 earnings report. What is new is the full set of results, now published in a peer-reviewed journal and presented at ObesityWeek.
Why are there two different weight loss numbers?
The 20.7% and 21.0% figures estimate what happens if everyone stays on the medicine. The 19.4% and 18.6% figures count everyone in the trial, including people who stopped. Both are real; the second is closer to everyday life.
Is the lower dose as good as the higher dose?
The two lower doses had similar results in this trial, but it was not designed to compare them with each other. The full 2.4/2.4 mg dose was tested in earlier REDEFINE trials.
When could CagriSema be approved?
Novo says it filed with the FDA in December 2025 for the 2.4/2.4 mg dose and expects a decision in the fourth quarter of 2026. It is not approved anywhere yet.
Does this change how I should eat on a GLP-1?
No. The trial did not test a diet; everyone got standard lifestyle support. Ask your care team about protein, portions and foods your stomach handles well.
Sources and credits
Follow the original sources for context and verification. A reference is not an endorsement of SmashMeals.
- Novo's investigational CagriSema demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology (opens in a new tab)
Novo Nordisk Inc.
Why it matters: The primary release with the trial design, both estimands, threshold results, discontinuation rates, FDA timing and the journal citation.
- Wharton S, Broholm C, Horn D, et al. Efficacy and safety of coadministered cagrilintide-semaglutide (CagriSema) 1.7 mg/1.7 mg and 1.0 mg/1.0 mg in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind, phase 3b trial (opens in a new tab)
The Lancet Diabetes & Endocrinology (published online Nov. 14, 2026), as cited by Novo Nordisk
Why it matters: The peer-reviewed paper behind the results.
- Novo Nordisk ObesityWeek 2026 data (opens in a new tab)
Novo Nordisk Inc.
Why it matters: Novo's Oct. 29 list of its ObesityWeek presentations, including food noise studies on the Wegovy pill and shot.